Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers

M. Plebani, F. Navaglia, D. Basso, M. De Paoli, M. O. Nicoletto, E. Maraglino, G. C. Torre

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

UGP, the β-core fragment of human chorionic gonadotrophin, has been proposed as a tumor marker for gynecological malignancies. This fragment may be detected in a single morning-specimen of urine using an enzyme immunoassay. In this study, the diagnostic usefulness of urine UGP and serum CA 125 measured for gynecological neoplasias (149 cases) was evaluated using a control group of patients with benign gynecological diseases (69 cases) and healthy females (99 cases). considering the neoplastic patients in comparison to patients with benign diseases, the best diagnostic efficiency of (78%) was found to correspond to a cut=off level of 120 pmol/mol creatinine the sensitivity being 73% and the specificity 90%. With this cut-off, an efficiency of 82% for healthy controls was obtained. Since the menopausal condition increases UGP levels, and though no significant difference for UGP was found between health subjects and patients with benign diseases, we decided to consider the reference populations as a single group. Thus, we evaluated the UGP performance on the basis of menopausal status. When a specificity of 95% was fixed, the cut-off values were 120 and 180 pmol/mol creatinine for pre- and postmenopausal women respectively, the sensitivity being 73% and 64%. Finally the combined evaluation of UGP and CA 125 improved the individual clinical efficiency for the diagnosis of ovarian serous cystadenocarcinomas, assuring a sensitivity of 86% and specificity of 89%.

Original languageEnglish
Pages (from-to)3833-3838
Number of pages6
JournalAnticancer Research
Volume16
Issue number6 B
Publication statusPublished - 1996

Fingerprint

Serum
Creatinine
Neoplasms
Serous Cystadenocarcinoma
Urine
Chorionic Gonadotropin
Tumor Biomarkers
Immunoenzyme Techniques
Sensitivity and Specificity
Control Groups
Health
Population
urinary gonadotropin fragment

Keywords

  • CA 125
  • Gynecological cancer
  • Receiver operating characteristic (ROC) curves
  • Sensitivity
  • Specificity
  • Tumor marker
  • UPG

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Plebani, M., Navaglia, F., Basso, D., De Paoli, M., Nicoletto, M. O., Maraglino, E., & Torre, G. C. (1996). Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers. Anticancer Research, 16(6 B), 3833-3838.

Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers. / Plebani, M.; Navaglia, F.; Basso, D.; De Paoli, M.; Nicoletto, M. O.; Maraglino, E.; Torre, G. C.

In: Anticancer Research, Vol. 16, No. 6 B, 1996, p. 3833-3838.

Research output: Contribution to journalArticle

Plebani, M, Navaglia, F, Basso, D, De Paoli, M, Nicoletto, MO, Maraglino, E & Torre, GC 1996, 'Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers', Anticancer Research, vol. 16, no. 6 B, pp. 3833-3838.
Plebani M, Navaglia F, Basso D, De Paoli M, Nicoletto MO, Maraglino E et al. Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers. Anticancer Research. 1996;16(6 B):3833-3838.
Plebani, M. ; Navaglia, F. ; Basso, D. ; De Paoli, M. ; Nicoletto, M. O. ; Maraglino, E. ; Torre, G. C. / Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers. In: Anticancer Research. 1996 ; Vol. 16, No. 6 B. pp. 3833-3838.
@article{300ea3fd6a734049990ee46bfddda4e6,
title = "Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers",
abstract = "UGP, the β-core fragment of human chorionic gonadotrophin, has been proposed as a tumor marker for gynecological malignancies. This fragment may be detected in a single morning-specimen of urine using an enzyme immunoassay. In this study, the diagnostic usefulness of urine UGP and serum CA 125 measured for gynecological neoplasias (149 cases) was evaluated using a control group of patients with benign gynecological diseases (69 cases) and healthy females (99 cases). considering the neoplastic patients in comparison to patients with benign diseases, the best diagnostic efficiency of (78{\%}) was found to correspond to a cut=off level of 120 pmol/mol creatinine the sensitivity being 73{\%} and the specificity 90{\%}. With this cut-off, an efficiency of 82{\%} for healthy controls was obtained. Since the menopausal condition increases UGP levels, and though no significant difference for UGP was found between health subjects and patients with benign diseases, we decided to consider the reference populations as a single group. Thus, we evaluated the UGP performance on the basis of menopausal status. When a specificity of 95{\%} was fixed, the cut-off values were 120 and 180 pmol/mol creatinine for pre- and postmenopausal women respectively, the sensitivity being 73{\%} and 64{\%}. Finally the combined evaluation of UGP and CA 125 improved the individual clinical efficiency for the diagnosis of ovarian serous cystadenocarcinomas, assuring a sensitivity of 86{\%} and specificity of 89{\%}.",
keywords = "CA 125, Gynecological cancer, Receiver operating characteristic (ROC) curves, Sensitivity, Specificity, Tumor marker, UPG",
author = "M. Plebani and F. Navaglia and D. Basso and {De Paoli}, M. and Nicoletto, {M. O.} and E. Maraglino and Torre, {G. C.}",
year = "1996",
language = "English",
volume = "16",
pages = "3833--3838",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers

AU - Plebani, M.

AU - Navaglia, F.

AU - Basso, D.

AU - De Paoli, M.

AU - Nicoletto, M. O.

AU - Maraglino, E.

AU - Torre, G. C.

PY - 1996

Y1 - 1996

N2 - UGP, the β-core fragment of human chorionic gonadotrophin, has been proposed as a tumor marker for gynecological malignancies. This fragment may be detected in a single morning-specimen of urine using an enzyme immunoassay. In this study, the diagnostic usefulness of urine UGP and serum CA 125 measured for gynecological neoplasias (149 cases) was evaluated using a control group of patients with benign gynecological diseases (69 cases) and healthy females (99 cases). considering the neoplastic patients in comparison to patients with benign diseases, the best diagnostic efficiency of (78%) was found to correspond to a cut=off level of 120 pmol/mol creatinine the sensitivity being 73% and the specificity 90%. With this cut-off, an efficiency of 82% for healthy controls was obtained. Since the menopausal condition increases UGP levels, and though no significant difference for UGP was found between health subjects and patients with benign diseases, we decided to consider the reference populations as a single group. Thus, we evaluated the UGP performance on the basis of menopausal status. When a specificity of 95% was fixed, the cut-off values were 120 and 180 pmol/mol creatinine for pre- and postmenopausal women respectively, the sensitivity being 73% and 64%. Finally the combined evaluation of UGP and CA 125 improved the individual clinical efficiency for the diagnosis of ovarian serous cystadenocarcinomas, assuring a sensitivity of 86% and specificity of 89%.

AB - UGP, the β-core fragment of human chorionic gonadotrophin, has been proposed as a tumor marker for gynecological malignancies. This fragment may be detected in a single morning-specimen of urine using an enzyme immunoassay. In this study, the diagnostic usefulness of urine UGP and serum CA 125 measured for gynecological neoplasias (149 cases) was evaluated using a control group of patients with benign gynecological diseases (69 cases) and healthy females (99 cases). considering the neoplastic patients in comparison to patients with benign diseases, the best diagnostic efficiency of (78%) was found to correspond to a cut=off level of 120 pmol/mol creatinine the sensitivity being 73% and the specificity 90%. With this cut-off, an efficiency of 82% for healthy controls was obtained. Since the menopausal condition increases UGP levels, and though no significant difference for UGP was found between health subjects and patients with benign diseases, we decided to consider the reference populations as a single group. Thus, we evaluated the UGP performance on the basis of menopausal status. When a specificity of 95% was fixed, the cut-off values were 120 and 180 pmol/mol creatinine for pre- and postmenopausal women respectively, the sensitivity being 73% and 64%. Finally the combined evaluation of UGP and CA 125 improved the individual clinical efficiency for the diagnosis of ovarian serous cystadenocarcinomas, assuring a sensitivity of 86% and specificity of 89%.

KW - CA 125

KW - Gynecological cancer

KW - Receiver operating characteristic (ROC) curves

KW - Sensitivity

KW - Specificity

KW - Tumor marker

KW - UPG

UR - http://www.scopus.com/inward/record.url?scp=0030499505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030499505&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 3833

EP - 3838

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -